Shak, S. 2009. Technological hurdles: Diagnostic developer perspective. PowerPoint presentation. Washington, DC: Genomic Health, Inc.

Smith, B. D., M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K. M. Murphy, T. Dauses, J. Allebach, and D. Small. 2004. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669–3676.

Sweet-Cordero, A., S. Mukherjee, A. Subramanian, H. You, J. J. Roix, C. Ladd-Acosta, J. Mesirov, T. R. Golub, and T. Jacks. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genetics 37(1):48–55.

Teutsch, S. M., L. A. Bradley, G. E. Palomaki, J. E. Haddow, M. Piper, N. Calonge, W. D. Dotson, M. P. Douglas, A. O. Berg, and E. W. Group. 2009. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genetics in Medicine 11(1):3–14.

van’t Veer, L. J., H. Dai, M. J. van de Vijver, Y. D. He, A. A. M. Hart, M. Mao, H. L. Peterse, K. van der Kooy, M. J. Marton, A. T. Witteveen, G. J. Schreiber, R. M. Kerkhoven, C. Roberts, P. S. Linsley, R. Bernards, and S. H. Friend. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536.

Vose, J., F. Loberiza, J. Armitage, P. Bierman, R. Bociek, and D. Dornan. 2009. Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab. Journal of Clinical Oncology (Meeting Abstracts) 27(15S): Abstract No: 8567.

Wolff, A. C., M. E. Hammond, J. N. Schwartz, K. L. Hagerty, D. C. Allred, R. J. Cote, M. Dowsett, P. L. Fitzgibbons, W. M. Hanna, A. Langer, L. M. McShane, S. Paik, M. D. Pegram, E. A. Perez, M. F. Press, A. Rhodes, C. Sturgeon, S. E. Taube, R. Tubbs, G. H. Vance, M. van de Vijver, T. M. Wheeler, D. F. Hayes, American Society of Clinical Oncology, and College of American Pathologists. 2007. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 25(1):118–145.

Woolf, S. H. 2008. The meaning of translational research and why it matters. JAMA 299(2):211–213.

Yang, X., J. L. Deignan, H. Qi, J. Zhu, S. Qian, J. Zhong, G. Torosyan, S. Majid, B. Falkard, R. R. Kleinhanz, J. Karlsson, L. W. Castellani, S. Mumick, K. Wang, T. Xie, M. Coon, C. Zhang, D. Estrada-Smith, C. R. Farber, S. S. Wang, A. van Nas, A. Ghazalpour, B. Zhang, D. J. MacNeil, J. R. Lamb, K. M. Dipple, M. L. Reitman, M. Mehrabian, P. Y. Lum, E. E. Schadt, A. J. Lusis, and T. A. Drake. 2009. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nature Genetics 41(4):415–423.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement